company background image
ATXS logo

Astria Therapeutics NasdaqGM:ATXS Stock Report

Last Price

US$10.14

Market Cap

US$577.3m

7D

-3.4%

1Y

88.8%

Updated

04 Dec, 2024

Data

Company Financials +

Astria Therapeutics, Inc.

NasdaqGM:ATXS Stock Report

Market Cap: US$577.3m

ATXS Stock Overview

A biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. More details

ATXS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Astria Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Astria Therapeutics
Historical stock prices
Current Share PriceUS$10.14
52 Week HighUS$16.90
52 Week LowUS$4.87
Beta0.67
11 Month Change-12.13%
3 Month Change-11.67%
1 Year Change88.83%
33 Year Change64.61%
5 Year Change-69.27%
Change since IPO-98.70%

Recent News & Updates

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Nov 27

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Nov 14
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Jul 11
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Jun 24

Recent updates

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Nov 27

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Nov 14
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Jul 11
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Jun 24

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Feb 04

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Dec 10
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Jul 27
We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Apr 03
We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Nov 30
Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Aug 01
We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Jul 15

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Jun 30

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Jun 15

Catabasis Pharma shares surge after Quellis Biosciences deal

Jan 29

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Dec 10
Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 29

Shareholder Returns

ATXSUS BiotechsUS Market
7D-3.4%-0.8%0.4%
1Y88.8%12.9%32.3%

Return vs Industry: ATXS exceeded the US Biotechs industry which returned 12.9% over the past year.

Return vs Market: ATXS exceeded the US Market which returned 32.3% over the past year.

Price Volatility

Is ATXS's price volatile compared to industry and market?
ATXS volatility
ATXS Average Weekly Movement9.1%
Biotechs Industry Average Movement10.0%
Market Average Movement6.3%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Stable Share Price: ATXS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ATXS's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200859Jill Milnewww.astriatx.com

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching.

Astria Therapeutics, Inc. Fundamentals Summary

How do Astria Therapeutics's earnings and revenue compare to its market cap?
ATXS fundamental statistics
Market capUS$577.32m
Earnings (TTM)-US$100.04m
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATXS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$100.04m
Earnings-US$100.04m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.77
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ATXS perform over the long term?

See historical performance and comparison